Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results